What are you talking about. We have been getting ample communication on 5461. I think it has been pretty transparent. Like any new drug especially a MDD drug that has an opioid component on board, there is no telling what the FDA will do. I think we are committed to the product and from what I understand we submitted an overwhelming amount of data with our submission. At the very least, that will help the FDA provide exactly what additional data they would like to see should we not get a full approval. The company has never told us that this is a 100% approval scenario. To the contrary. We have been told 70% of wall street thinks it will not get approved. We have been told that this is a unique compound that will most likely garner substantial scrutiny from the FDA. We have also been informed that we have submitted an impressive amount of data and we are committed to helping people with MDD. Should the FDA want an additional efficacy study or longer term or more detailed potential for addiction or misuse studies we have an ample pool of information that has been submitted to build on and hopefully be able to provide that in months instead of a year or more. And who knows, maybe all the data we submitted will be enough to get a first go round approval. You never know with the FDA and I think the company has been pretty honest with us about that and ethical with and supportive of the FDA.
As for layoffs, I don't understand why you would say that. Vivitrol is growing nicely and Aristada is really starting to pick up. The expansion offers are going to be contingent on 5461 from my understanding and any expansion for Aristada alone is very small. I don't get the layoff comment at all.